STOCK TITAN

[144] Incyte Genomics Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Incyte Genomics Inc (INCY) filed a Form 144 reporting a proposed sale of 277 common shares on 08/15/2025 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $24,046.37 and shows 195,276,145 shares outstanding, and the shares were acquired the same day via a stock option exercise with payment in cash.

The filing also discloses five recent sales by Sheila Denton within the prior three months: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and the form identifies Morgan Stanley as broker of record.

Incyte Genomics Inc (INCY) ha depositato un Form 144 indicando la proposta di vendita di 277 azioni ordinarie il 15/08/2025 tramite Morgan Stanley Smith Barney LLC. La dichiarazione riporta un valore di mercato complessivo di $24.046,37, indica 195.276.145 azioni in circolazione e specifica che le azioni sono state acquisite lo stesso giorno mediante un esercizio di opzioni su azioni con pagamento in contanti.

Il documento segnala inoltre cinque vendite recenti effettuate da Sheila Denton nei tre mesi precedenti: 1.795 azioni il 03/06/2025; 599 il 02/07/2025; 3.330 il 15/07/2025; 785 il 16/07/2025; e 598 il 04/08/2025, con i proventi lordi dichiarati per ciascuna vendita. Il dichiarante certifica l'assenza di informazioni materiali non divulgate e il form indica Morgan Stanley come broker incaricato.

Incyte Genomics Inc (INCY) presentó un Formulario 144 informando la propuesta de venta de 277 acciones ordinarias el 15/08/2025 a través de Morgan Stanley Smith Barney LLC. La presentación indica un valor de mercado agregado de $24,046.37, muestra 195,276,145 acciones en circulación y señala que las acciones se adquirieron el mismo día mediante un ejercicio de opción sobre acciones con pago en efectivo.

El documento también revela cinco ventas recientes de Sheila Denton en los tres meses previos: 1,795 acciones el 03/06/2025; 599 el 02/07/2025; 3,330 el 15/07/2025; 785 el 16/07/2025; y 598 el 04/08/2025, con los ingresos brutos reportados para cada venta. El declarante certifica que no hay información material no divulgada y el formulario identifica a Morgan Stanley como el corredor de registro.

Incyte Genomics Inc (INCY)는 Morgan Stanley Smith Barney LLC를 통해 2025년 8월 15일277주 보통주 매도를 제안하는 Form 144를 제출했습니다. 제출서에는 총시장가치 $24,046.37이 기재되어 있고, 195,276,145주의 발행주식수를 표시하며, 해당 주식은 같은 날 스톡옵션 행사로 현금 지급을 통해 취득되었다고 명시되어 있습니다.

또한 제출서는 Sheila Denton이 최근 3개월 내에 한 다섯 건의 매도를 공개하고 있습니다: 2025-06-03에 1,795주; 2025-07-02에 599주; 2025-07-15에 3,330주; 2025-07-16에 785주; 2025-08-04에 598주이며, 각 매도에 대한 총수익이 보고되어 있습니다. 제출자는 미공개 중대한 정보가 없음을 인증하며, 서식은 Morgan Stanley를 명목 중개인으로 지정하고 있습니다.

Incyte Genomics Inc (INCY) a déposé un formulaire 144 signalant une proposition de vente de 277 actions ordinaires le 15/08/2025 via Morgan Stanley Smith Barney LLC. Le dépôt indique une valeur de marché agrégée de $24,046.37, mentionne 195,276,145 actions en circulation et précise que les actions ont été acquises le même jour par exercice d'option sur actions avec paiement en espèces.

Le document révèle également cinq ventes récentes réalisées par Sheila Denton au cours des trois mois précédents : 1 795 actions le 03/06/2025 ; 599 le 02/07/2025 ; 3 330 le 15/07/2025 ; 785 le 16/07/2025 ; et 598 le 04/08/2025, avec le produit brut déclaré pour chaque vente. Le déclarant certifie qu'il n'existe pas d'informations matérielles non divulguées et le formulaire identifie Morgan Stanley comme courtier enregistré.

Incyte Genomics Inc (INCY) hat ein Formular 144 eingereicht, in dem ein geplanter Verkauf von 277 Stammaktien am 15.08.2025 über Morgan Stanley Smith Barney LLC gemeldet wird. Die Einreichung nennt einen aggregierten Marktwert von $24.046,37, weist 195.276.145 ausstehende Aktien aus und gibt an, dass die Aktien am selben Tag durch Ausübung einer Aktienoption mit Barzahlung erworben wurden.

Das Formular legt außerdem fünf jüngste Verkäufe von Sheila Denton innerhalb der vorangegangenen drei Monate offen: 1.795 Aktien am 03.06.2025; 599 am 02.07.2025; 3.330 am 15.07.2025; 785 am 16.07.2025; und 598 am 04.08.2025, jeweils mit den berichteten Bruttoerlösen. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen Informationen vorliegen, und das Formular benennt Morgan Stanley als registrierten Broker.

Positive
  • Required disclosure provided for proposed sale including broker, acquisition method, payment type, and aggregate market value
  • Recent sales history disclosed for the past three months, enhancing transparency
Negative
  • Insider selling activity by the same individual (multiple transactions totaling several thousand shares) could be viewed unfavorably by some investors
  • Form lacks issuer identity details in the provided content (issuer address and SEC file number are not shown)

Insights

TL;DR Insider exercised options and plans a small secondary sale; recent insider dispositions are disclosed but represent a tiny fraction of outstanding stock.

The filing documents a routine Form 144 tied to a same-day stock option exercise and a proposed sale of 277 shares valued at about $24k. With 195.3 million shares outstanding, the planned sale is immaterial to capitalization. Recent sales by the same individual show ongoing liquidity events but no indication of company-level disclosure issues. For investors, these are compliance-level disclosures rather than signals of operational change.

TL;DR Form 144 appears complete for the transaction and includes required past three-month sales; signature and broker details are provided.

The form lists the broker (Morgan Stanley Smith Barney LLC), acquisition method (stock option exercise), payment type (cash), and aggregates recent dispositions by the seller, satisfying Rule 144 notice elements. The filer makes the standard representation regarding material nonpublic information. No procedural or disclosure deficiencies are apparent from the text provided.

Incyte Genomics Inc (INCY) ha depositato un Form 144 indicando la proposta di vendita di 277 azioni ordinarie il 15/08/2025 tramite Morgan Stanley Smith Barney LLC. La dichiarazione riporta un valore di mercato complessivo di $24.046,37, indica 195.276.145 azioni in circolazione e specifica che le azioni sono state acquisite lo stesso giorno mediante un esercizio di opzioni su azioni con pagamento in contanti.

Il documento segnala inoltre cinque vendite recenti effettuate da Sheila Denton nei tre mesi precedenti: 1.795 azioni il 03/06/2025; 599 il 02/07/2025; 3.330 il 15/07/2025; 785 il 16/07/2025; e 598 il 04/08/2025, con i proventi lordi dichiarati per ciascuna vendita. Il dichiarante certifica l'assenza di informazioni materiali non divulgate e il form indica Morgan Stanley come broker incaricato.

Incyte Genomics Inc (INCY) presentó un Formulario 144 informando la propuesta de venta de 277 acciones ordinarias el 15/08/2025 a través de Morgan Stanley Smith Barney LLC. La presentación indica un valor de mercado agregado de $24,046.37, muestra 195,276,145 acciones en circulación y señala que las acciones se adquirieron el mismo día mediante un ejercicio de opción sobre acciones con pago en efectivo.

El documento también revela cinco ventas recientes de Sheila Denton en los tres meses previos: 1,795 acciones el 03/06/2025; 599 el 02/07/2025; 3,330 el 15/07/2025; 785 el 16/07/2025; y 598 el 04/08/2025, con los ingresos brutos reportados para cada venta. El declarante certifica que no hay información material no divulgada y el formulario identifica a Morgan Stanley como el corredor de registro.

Incyte Genomics Inc (INCY)는 Morgan Stanley Smith Barney LLC를 통해 2025년 8월 15일277주 보통주 매도를 제안하는 Form 144를 제출했습니다. 제출서에는 총시장가치 $24,046.37이 기재되어 있고, 195,276,145주의 발행주식수를 표시하며, 해당 주식은 같은 날 스톡옵션 행사로 현금 지급을 통해 취득되었다고 명시되어 있습니다.

또한 제출서는 Sheila Denton이 최근 3개월 내에 한 다섯 건의 매도를 공개하고 있습니다: 2025-06-03에 1,795주; 2025-07-02에 599주; 2025-07-15에 3,330주; 2025-07-16에 785주; 2025-08-04에 598주이며, 각 매도에 대한 총수익이 보고되어 있습니다. 제출자는 미공개 중대한 정보가 없음을 인증하며, 서식은 Morgan Stanley를 명목 중개인으로 지정하고 있습니다.

Incyte Genomics Inc (INCY) a déposé un formulaire 144 signalant une proposition de vente de 277 actions ordinaires le 15/08/2025 via Morgan Stanley Smith Barney LLC. Le dépôt indique une valeur de marché agrégée de $24,046.37, mentionne 195,276,145 actions en circulation et précise que les actions ont été acquises le même jour par exercice d'option sur actions avec paiement en espèces.

Le document révèle également cinq ventes récentes réalisées par Sheila Denton au cours des trois mois précédents : 1 795 actions le 03/06/2025 ; 599 le 02/07/2025 ; 3 330 le 15/07/2025 ; 785 le 16/07/2025 ; et 598 le 04/08/2025, avec le produit brut déclaré pour chaque vente. Le déclarant certifie qu'il n'existe pas d'informations matérielles non divulguées et le formulaire identifie Morgan Stanley comme courtier enregistré.

Incyte Genomics Inc (INCY) hat ein Formular 144 eingereicht, in dem ein geplanter Verkauf von 277 Stammaktien am 15.08.2025 über Morgan Stanley Smith Barney LLC gemeldet wird. Die Einreichung nennt einen aggregierten Marktwert von $24.046,37, weist 195.276.145 ausstehende Aktien aus und gibt an, dass die Aktien am selben Tag durch Ausübung einer Aktienoption mit Barzahlung erworben wurden.

Das Formular legt außerdem fünf jüngste Verkäufe von Sheila Denton innerhalb der vorangegangenen drei Monate offen: 1.795 Aktien am 03.06.2025; 599 am 02.07.2025; 3.330 am 15.07.2025; 785 am 16.07.2025; und 598 am 04.08.2025, jeweils mit den berichteten Bruttoerlösen. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen Informationen vorliegen, und das Formular benennt Morgan Stanley als registrierten Broker.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for INCY report?

The Form 144 reports a proposed sale of 277 common shares of INCY on 08/15/2025 via Morgan Stanley, with aggregate market value $24,046.37.

How were the 277 INCY shares acquired according to the filing?

The shares were acquired on 08/15/2025 through a stock option exercise and payment was made in cash.

Who is the broker handling the proposed INCY sale?

The filing names Morgan Stanley Smith Barney LLC as the broker for the proposed sale.

What recent insider sales by the seller are reported for INCY?

The filing lists sales by Sheila Denton: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds shown for each sale.

How material is the proposed 277-share sale relative to INCY outstanding shares?

With 195,276,145 shares outstanding, the proposed sale of 277 shares is immaterial to the company’s total market capitalization.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

16.83B
190.93M
2.03%
103.51%
3.8%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON